Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underway
As many as 170 new anti-obesity drugs are in various stages of development — from preclinical evaluation to advanced trials — though medical experts advise caution against their harmful effects due to reckless self-medication. Data collated from the obesity drugs tracker of Stat News, a popular Boston-based website on medical and healthcare analytical and investigative news, show Amgen, AstraZeneca, Boehringer Ingelheim, Roche and Regeneron are among the big names that are part of the choking pipeline.
However, giants like Swiss drug maker Novartis and UK-based GSK are taking a cautious view of the opportunity.
Pfizer had a setback recently with its experimental pill danuglipron that resulted in liver injury in a patient during the clinical trials. Eli Lilly, which is seeing record-shattering sales, with its Zepbound/Mounjaro brands, has at least nine drugs listed in active research. Its Danish rival Novo Nordisk is working on 14 leads, including additional studies on the already approved products.
In a mailed response to ET, an Eli Lilly India spokesperson said the company invests approximately 25% of its revenue in R&D, significantly exceeding industry benchmarks. 'We are strategically focusing on areas of high unmet need, such as obesity, a chronic disease that requires more effective treatment options. Our goal is to modernise how this disease is approached, and we are making bold, science-driven decisions to explore new treatment modalities,' she said. Referring to orforglipron, its nonpeptide, oral GLP-1 receptor agonist being studied for the treatment of obesity and type-2 diabetes, the Lilly spokesperson said, 'We've seen so far, we have a high degree of confidence on what this molecule could mean for patients.' But several drugs on the Stat News tracker are once-a-week injectables with the sole exception of San Diego-based Skye Bioscience, which is developing a once a-month injectable drug. Interestingly, like orforglipron, at least 64 drugs being developed are in the oral or pill form, marking a shift that will make dosing compliance easier and result in lower manufacturing costs than the injectables. A growing number of Chinese companies including Innovent, Sciwind, Zhejiang Doer, Innogen and Jiangsu Hengrui are catching up with their western counterparts on the back of speedy trials and conducive regulatory pathways, while India's Sun Pharma is the only one from the country that is listed to develop its own molecule utreglutide in earlystages of clinical trials.
The other big names from India such as Dr Reddy's, Biocon, Cipla and Torrent are developing copies of semaglutide, which is pending patent expiry early next year.
FRONTLINE STRATEGY AGAINST NCDS
Diabetologist and obesity expert Rajiv Kovil told ET that the emergence of powerful anti-obesity therapies is driving a fundamental shift in the treatment of non-communicable diseases (NCDs). Now, he says, obesity care is no longer an afterthought, it's becoming the frontline strategy against NCDs. Stat News data show the areas of research for obesity drugs is rapidly expanding beyond targeting the GLP-1 gut hormones. Currently multiple modalities are being approached like silencing certain genes using the RNA interference technology that may have a longer effect than the injectables. Another biologic pathway is to target amylin, a hormone secreted by pancreas and has a role in stomach emptying and reduced calorie intake, without causing nausea or muscle loss. Some of the research involves combining multiple targets like GLP-1/GIP and amylin analogues.
The competitive landscape is expected to change as at least 10 drugs are in phase-III clinical trials, the stage before which regulatory agencies grant marketing approvals. Besides the benefits in weight loss, the new experiments on an array of conditions are underway. Those include MASH (metabolic dysfunction-associated steatohepatitis), cardiovascular disease (CVD), obstructive sleep apnea, neurological disorders like Alzheimer's disease, polycystic ovary syndrome (PCOS), chronic kidney disease (CKD), heart failures and arthritis.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 hours ago
- The Hindu
11 free paediatric heart surgeries performed by Andhra Hospitals
The 35th Paediatric Cardiac Surgical Camp organised by the Heart and Brain Institute of Andhra Hospitals in association with a team from UK-based Healing Little Hearts concluded on Saturday (August 2, 2025). The camp commenced on July 28. At a press conference on Sunday (August 3, 2025), Chief of Children's Services and Director of the Hospital Dr. P. V. Rama Rao said that consultant paediatric cardiac surgeon Dr B. R. Jagannath from Shri Madhusudan Sai Hospital at Muddenahalli in Bengaluru along with Andhra Hospitals cardiac surgical team led by Dr. Nageswara Rao, completed 11 free heart surgeries. The team performed very complex heart surgeries for conditions like Total Anomalous Pulmonary Venous Drainage (TAPVD), Partial Anomalous Pulmonary Venous Drainage (PAPVD), TOF and PA banding among other surgeries, he said, adding that the success rate of the surgeries was nearly 99% and which is because of the team effort. He said so far, the hospital had successfully performed more than 4,800 cardiac surgeries and interventions. Representatives of the Healing Little Hearts, UK team, have visited the hospital 34 times so far and many complex heart surgeries were performed with their association, he added. Senior paediatric cardiologist Dr. Vikram, Paediatric cardiologist Dr. Sk. Moinuddin Chisty, senior cardiac surgeon Dr. Nageswara Rao, senior cardiac anaesthetist Dr. Ramesh and cardiologists Dr. Raghuram, and Dr. Tirupathi Rao were also present at the press meet.
Time of India
4 hours ago
- Time of India
Manipal Hospitals seeks CCI nod to acquire Sahyadri Hospitals for about Rs 6,400 cr
New Delhi: Healthcare major Manipal Hospitals has sought approval from the fair trade regulator CCI to acquire Pune-based Sahyadri Hospitals from global investor Ontario Teachers' Pension Plan Board in a deal pegged at around Rs 6,400 crore. The companies did not share the deal size, but industry sources estimate the transaction to be in the range of Rs 6,200-6,400 crore. "The proposed transaction envisages the acquisition of up to 100 per cent shareholding by the acquirer (Manipal Hospitals Pvt Ltd) in the target (Sahyadri Hospitals Pvt Ltd) in multiple tranches," according to a notice filed with the Competition Commission of India (CCI). Manipal Hospitals and Sahyadri Hospitals said the "proposed transaction does not have any impact on any relevant market in India, let alone any appreciable adverse effect on competition (AAEC), and therefore, the definition of the relevant product and geographic market may ultimately be left open. In any event, in order to aid and assist the CCI in its assessment". Last month, Manipal Hospitals announced that it had inked definitive agreements with Ontario Teachers' for the acquisition. The Bengaluru-based healthcare major said the acquisition of Sahyadri Hospitals will bring Manipal's total bed count to about 12,000, making it one of India's largest hospital networks. The acquisition will add 11 hospitals to Manipal's network across Pune, Nashik, Ahilya Nagar and Karad, increasing its total number of hospitals to 49, it added. Through this acquisition, Manipal said it will expand its presence in western India, in line with its strategy to augment its pan-India footprint. "With the strong partnership of our valued stakeholders like Temasek and our other investors, we are excited to grow our operations and bring Manipal's trusted brand of quality healthcare to many more patients," Manipal Health Enterprises MD and CEO Dilip Jose said. Manipal Education and Medical Group (MEMG) Chairman Ranjan Pai said the acquisition will strengthen Manipal's presence in western India. "With this expansion, Manipal Hospitals will have a network of approximately 12,000 beds nationwide, solidifying our position as one of the largest hospital chains in India," he added. Manipal Hospitals is backed by Temasek, a global investment company, headquartered in Singapore, with a net portfolio value of around USD 324 billion as of March 31, 2025. A global investor with net assets of USD 266.3 billion as of December 31, 2024, Ontario Teachers' Pension Plan Board (Ontario Teachers') acquired a majority stake in Sahyadri in 2022. The Pune-based hospital chain is now one of Maharashtra's largest, with 11 hospitals and over 1,400 beds.
Hindustan Times
4 hours ago
- Hindustan Times
Gastroenterologist explains why those who undergo drastic weightloss often regain the kilos; who is at greater risk
How inspiring does it feel when we see a friend or even a celebrity shed the extra pounds to reveal a fit and toned self. They work out at the gym, keep their diet in check and impress one and all with their dedication. However, the lost kilos do not always stay off. Many often pack on those pounds again, often in no time at all. Why does that happen and why do some people find it so hard to stay lean and fit? Sustainable weight loss involves building healthy habits rather than quick fixes, as fat cells shrink but do not disappear during dieting. Why can't we keep the shed weight off? Gastroenterologist Dr Palaniappan Manickam shared a video recently on Instagram on this topic. The California-based doctor explained why individuals often regain weight after dieting, attributing this phenomenon to fat cells that shrink but do not vanish, similar to deflating balloons. 'Have you ever wondered why you gain back all the weight after a diet? It is not your fault. It is your fat cells. When you go on a diet and eat fewer calories, your fat cells shrink. But they do not disappear. They just deflate like a balloon. And the second you start eating more again, they inflate right back. That's why that weight that you lost comes back so fast,' he said in the video. He added that the number of fat cells is typically set after the teenage years, suggesting that individuals who were overweight during their youth may have a higher baseline number. Teenage years set the course 'And what most people don't know is your body stops making new fat cells after your teenage years. So if you are overweight during your teens, you probably have more fat cells than others. That's why people who are overweight early in life may find it harder to manage their weight in adulthood. So when you lose fat too fast, those fat cells start screaming for food and that is why crash diets feel impossible to stick to,' he added. 'This is why sustainable weight loss matters. The goal is not just to lose fat. It is to build healthy habits that improve your energy, digestion, and sleep where weight loss becomes a natural side effect of your process.' Wondering how to achieve sustainable weight loss? It includes making staying active and eating right a part of your daily life and not just a momentary exercise to be followed for a few months. Follow this five-step guide by fitness coach Rajni Singh to achieve sustainable weight loss. She shows how to 'cut through the noise if you're serious about changing your body—your energy, your strength, your confidence—it comes down to the basics. Not trends, not shortcuts. Just real, sustainable habits.' Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
